+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Adeno-Associated Virus Vector Production CDMO Market - Global Forecast 2025-2030- Product Image
Adeno-Associated Virus Vector Production CDMO Market - Global Forecast 2025-2030- Product Image
Sale

Adeno-Associated Virus Vector Production CDMO Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6118405
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Advances in gene therapy are rapidly transforming the adeno-associated virus (AAV) vector contract development and manufacturing organization (CDMO) landscape. Senior decision-makers across life sciences now face increasingly complex considerations for service provider selection, as integrating cutting-edge analytical services, robust process innovation, and compliant manufacturing is essential for meeting therapeutic pipeline needs.

Market Snapshot: AAV Vector CDMO Industry Outlook

The global AAV vector CDMO market is experiencing accelerated growth, driven by technology advancements, evolving regulatory expectations, and increasing gene therapy clinical activity. Market momentum is shaped by the adoption of scalable production platforms, the emergence of flexible service models, and rising investment in streamlined manufacturing solutions. Strategic regional expansions and robust capital inflows have positioned leading CDMOs to address diverse needs from preclinical development to commercial supply. The sector reflects significant opportunity for agile providers who align operational capabilities with both clinical and regulatory demands.

Scope & Segmentation of the AAV Vector CDMO Market

  • Service Type: Analytical services (potency and purity assays), downstream processing (affinity chromatography, ion exchange chromatography, tangential flow filtration), fill-finish (pre-filled syringe, vial filling), and upstream processing (stable expression, transient transfection).
  • Production Scale: Clinical (across all phases), commercial, preclinical.
  • Expression System: HEK293, Sf9.
  • Production Platform: Stable producer cell line including proprietary GTx platforms, and transient transfection using liposome and polyethylenimine reagents.
  • Therapeutic Application: Genetic diseases (hemophilia, muscular dystrophy), neurological disorders (Alzheimer’s disease, Parkinson’s disease), oncology.
  • End User: Academic research institutes, biotechnology companies, pharmaceutical companies.
  • Serotype: AAV2, AAV8, AAV9.
  • Regional Coverage: Markets across the Americas (including United States, California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio, Canada, Mexico, Brazil, Argentina), Europe, Middle East, Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), and Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Key Providers Covered: Lonza Group AG, Catalent, Inc., Thermo Fisher Scientific Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Wuxi AppTec Co., Ltd., AGC Biologics Co., Ltd., Merck KGaA, Charles River Laboratories International, Inc., VGXI LLC, GenScript Biotech Corporation.

Key Takeaways: Strategic Insights for Growth and Efficiency

  • Technology integration, such as real-time process analytics and advanced purification, is reshaping clinical and commercial readiness for gene therapy manufacturing.
  • Co-development partnerships with biotech and academic institutes are expanding access to novel expression systems and new transfection technologies.
  • Flexible platform adoption supports both stable cell lines and transient transfection, mitigating single-source dependency risks and improving scalability.
  • The regulatory landscape is gaining complexity, increasing demand for comprehensive analytical services and robust quality assurance frameworks.
  • Regional manufacturing strategies—boosted by localization and public-private partnerships—have become critical for optimizing project timelines and supply reliability.
  • High-value service differentiation includes multiproduct analytical suites, niche serotype characterization, and streamlined fill-finish operations.

Tariff Impact: Navigating the U.S. 2025 Tariff Framework

Revised U.S. tariffs introduced in 2025 are adding complexity to supply chain management for AAV vector CDMOs, affecting the cost of raw materials and critical equipment. Providers are reevaluating supplier portfolios, pursuing localization, and negotiating long-term sourcing as import duties increase expenses on chromatography materials, single-use components, and transfection reagents. Operational adjustments—such as optimizing buffer preparation and consolidating logistics—aim to offset these pressures and maintain quality benchmarks within budget constraints.

Market Research Methodology & Data Sources

This report synthesizes insights from primary expert interviews with CDMO executives, biotechnology leaders, and regulatory specialists, as well as peer-reviewed journals, patents, and industry publications. Statistical techniques and cross-verified databases were used to analyze technology adoption and investment patterns. All findings have undergone iterative expert review and quality assurance checks to ensure balanced and comprehensive coverage.

Why This AAV Vector CDMO Report Matters

  • Enables executives to evaluate providers and technology investments in a dynamic, regulatory-driven landscape.
  • Supports decision-making on regional expansion, service differentiation, and operational resilience amid shifting supply and policy conditions.
  • Delivers actionable segmentation and competitive mapping to inform late-stage development and commercial launch planning.

Conclusion

AAV vector CDMO stakeholders can leverage this report to align capabilities, navigate evolving regulatory and market forces, and capture emerging opportunities in gene therapy development. Strategic integration and continuous operational improvement remain key to sustaining long-term success.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increased adoption of single-use bioreactor systems for scalable AAV vector production and reduced cross-contamination risks
5.2. Integration of advanced chromatographic purification technologies to enhance large-scale AAV vector yield and purity
5.3. Development of novel suspension cell lines engineered for high-yield serotype-specific AAV vector production
5.4. Implementation of continuous processing approaches to optimize upstream and downstream AAV vector manufacturing efficiency
5.5. Strategic partnerships between CDMOs and academic labs to accelerate next-generation AAV engineered capsid translation
5.6. Regulatory framework harmonization initiatives aimed at streamlining global AAV vector clinical trial approvals
5.7. Digitalization and automation of AAV manufacturing workflows through AI-driven process monitoring and predictive analytics
5.8. Cost reduction strategies leveraging process intensification techniques and modular facility designs in AAV CDMO operations
5.9. Expansion of in-house quality control and advanced analytics capabilities enabling real-time release testing for AAV vectors
5.10. Integration of gene editing platforms within AAV manufacturing pipelines to support complex gene therapy payload production
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Adeno-Associated Virus Vector Production CDMO Market, by Service Type
8.1. Introduction
8.2. Analytical Services
8.2.1. Potency Assay
8.2.2. Purity Assay
8.3. Downstream Processing
8.3.1. Chromatography
8.3.1.1. Affinity Chromatography
8.3.1.2. Ion Exchange Chromatography
8.3.2. Ultrafiltration
8.3.2.1. Tangential Flow Filtration
8.4. Fill Finish
8.4.1. Pre Fill Syringe
8.4.2. Vial Filling
8.5. Upstream Processing
8.5.1. Stable Expression
8.5.2. Transient Transfection
9. Adeno-Associated Virus Vector Production CDMO Market, by Production Scale
9.1. Introduction
9.2. Clinical
9.2.1. Phase One
9.2.2. Phase Three
9.2.3. Phase Two
9.3. Commercial
9.4. Preclinical
10. Adeno-Associated Virus Vector Production CDMO Market, by Expression System
10.1. Introduction
10.2. HEK293
10.3. Sf9
11. Adeno-Associated Virus Vector Production CDMO Market, by Production Platform
11.1. Introduction
11.2. Stable Producer Cell Line
11.2.1. GTx Platform
11.3. Transient Transfection
11.3.1. Liposome Transfection
11.3.2. Polyethylenimine Transfection
12. Adeno-Associated Virus Vector Production CDMO Market, by Therapeutic Application
12.1. Introduction
12.2. Genetic Diseases
12.2.1. Hemophilia
12.2.2. Muscular Dystrophy
12.3. Neurological Disorders
12.3.1. Alzheimers Disease
12.3.2. Parkinsons Disease
12.4. Oncology
13. Adeno-Associated Virus Vector Production CDMO Market, by End User
13.1. Introduction
13.2. Academic Research Institutes
13.3. Biotechnology Companies
13.4. Pharmaceutical Companies
14. Adeno-Associated Virus Vector Production CDMO Market, by Serotype
14.1. Introduction
14.2. AAV2
14.3. AAV8
14.4. AAV9
15. Americas Adeno-Associated Virus Vector Production CDMO Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Adeno-Associated Virus Vector Production CDMO Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Adeno-Associated Virus Vector Production CDMO Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Lonza Group AG
18.3.2. Catalent, Inc.
18.3.3. Thermo Fisher Scientific Inc.
18.3.4. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
18.3.5. Wuxi AppTec Co., Ltd.
18.3.6. AGC Biologics Co., Ltd.
18.3.7. Merck KGaA
18.3.8. Charles River Laboratories International, Inc.
18.3.9. VGXI LLC
18.3.10. GenScript Biotech Corporation
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY EXPRESSION SYSTEM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY EXPRESSION SYSTEM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SEROTYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SEROTYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET: RESEARCHAI
FIGURE 30. ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET: RESEARCHSTATISTICS
FIGURE 31. ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET: RESEARCHCONTACTS
FIGURE 32. ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY POTENCY ASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY POTENCY ASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PURITY ASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PURITY ASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ULTRAFILTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ULTRAFILTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TANGENTIAL FLOW FILTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TANGENTIAL FLOW FILTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ULTRAFILTRATION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ULTRAFILTRATION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRE FILL SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRE FILL SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY VIAL FILLING, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY VIAL FILLING, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STABLE EXPRESSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STABLE EXPRESSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PHASE ONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PHASE ONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PHASE THREE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PHASE THREE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PHASE TWO, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PHASE TWO, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COMMERCIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRECLINICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY HEK293, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY HEK293, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SF9, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SF9, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STABLE PRODUCER CELL LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STABLE PRODUCER CELL LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GTX PLATFORM, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GTX PLATFORM, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STABLE PRODUCER CELL LINE, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STABLE PRODUCER CELL LINE, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY LIPOSOME TRANSFECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY LIPOSOME TRANSFECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY POLYETHYLENIMINE TRANSFECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY POLYETHYLENIMINE TRANSFECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY HEMOPHILIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY MUSCULAR DYSTROPHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY MUSCULAR DYSTROPHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ALZHEIMERS DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ALZHEIMERS DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PARKINSONS DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PARKINSONS DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SEROTYPE, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SEROTYPE, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY AAV2, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY AAV2, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY AAV8, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY AAV8, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY AAV9, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY AAV9, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ULTRAFILTRATION, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ULTRAFILTRATION, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STABLE PRODUCER CELL LINE, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STABLE PRODUCER CELL LINE, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SEROTYPE, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SEROTYPE, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ULTRAFILTRATION, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ULTRAFILTRATION, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STABLE PRODUCER CELL LINE, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STABLE PRODUCER CELL LINE, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SEROTYPE, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SEROTYPE, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 203. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 204. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 205. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 206. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 207. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 208. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 209. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
TABLE 210. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, 2025-2030 (USD MILLION)
TABLE 211. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ULTRAFILTRATION, 2018-2024 (USD MILLION)
TABLE 212. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ULTRAFILTRATION, 2025-2030 (USD MILLION)
TABLE 213. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, 2018-2024 (USD MILLION)
TABLE 214. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, 2025-2030 (USD MILLION)
TABLE 215. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 216. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 217. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
TABLE 218. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2025-2030 (USD MILLION)
TABLE 219. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 220. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 221. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
TABLE 222. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2030 (USD MILLION)
TABLE 223. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2024 (USD MILLION)
TABLE 224. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2025-2030 (USD MILLION)
TABLE 225. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STABLE PRODUCER CELL LINE, 2018-2024 (USD MILLION)
TABLE 226. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STABLE PRODUCER CELL LINE, 2025-2030 (USD MILLION)
TABLE 227. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 228. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 229. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 230. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 231. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, 2018-2024 (USD MILLION)
TABLE 232. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, 2025-2030 (USD MILLION)
TABLE 233. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 234. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 235. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SEROTYPE, 2018-2024 (USD MILLION)
TABLE 238. CANADA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SEROTYPE, 2025-2030 (USD MILLION)
TABLE 239. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 240. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 241. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 242. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 243. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 244. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 245. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
TABLE 246. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, 2025-2030 (USD MILLION)
TABLE 247. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ULTRAFILTRATION, 2018-2024 (USD MILLION)
TABLE 248. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ULTRAFILTRATION, 2025-2030 (USD MILLION)
TABLE 249. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, 2018-2024 (USD MILLION)
TABLE 250. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, 2025-2030 (USD MILLION)
TABLE 251. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 252. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 253. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
TABLE 254. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2025-2030 (USD MILLION)
TABLE 255. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
TABLE 256. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
TABLE 257. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
TABLE 258. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2030 (USD MILLION)
TABLE 259. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2024 (USD MILLION)
TABLE 260. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2025-2030 (USD MILLION)
TABLE 261. MEXICO ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STABLE PRODUCER CELL LINE, 2018-20

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Adeno-Associated Virus Vector Production CDMO market report include:
  • Lonza Group AG
  • Catalent, Inc.
  • Thermo Fisher Scientific Inc.
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • Wuxi AppTec Co., Ltd.
  • AGC Biologics Co., Ltd.
  • Merck KGaA
  • Charles River Laboratories International, Inc.
  • VGXI LLC
  • GenScript Biotech Corporation

Related Topics

Related Reports

Adeno-Associated Virus (AAV) CDMO Services Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Adeno-Associated Virus (AAV) CDMO Services Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Cell Therapy & Gene Therapy CDMO Market - Global Forecast 2025-2030 - Product Image

Cell Therapy & Gene Therapy CDMO Market - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Cell & Gene Therapy Biomanufacturing CDMO Market - Global Forecast 2025-2030 - Product Image

Cell & Gene Therapy Biomanufacturing CDMO Market - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Report 2025 - Product Image

Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Market Report 2025

  • Report
  • 200 Pages
  • Global
From
CDMO Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2025-2034) - Product Image

CDMO Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2025-2034)

  • Report
  • 350 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.